Share Price and Basic Stock Data
Last Updated: December 8, 2025, 4:17 pm
| PEG Ratio | 6.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Colinz Laboratories Ltd operates in the pharmaceuticals sector, where it has demonstrated a steady yet modest revenue trajectory. For the fiscal year ending March 2025, the company reported sales of ₹6.53 Cr, a slight decline from the previous year’s ₹7.03 Cr. This trend reflects a challenging environment, as sales have fluctuated over the past few quarters, with the latest quarterly figure for June 2025 standing at ₹1.57 Cr. This variability in sales indicates potential headwinds in demand or competitive pressures. The company has maintained a consistent sales presence, with TTM revenue at ₹6.35 Cr, suggesting that while it has weathered recent challenges, it may need to innovate or adjust strategies to enhance growth. The operating profit margin has hovered around 7.50% to 8.81%, showing some resilience, but it remains lower than many of its peers, indicating a need for improved cost management or pricing strategies.
Profitability and Efficiency Metrics
Colinz’s profitability metrics present a mixed picture. The net profit for FY 2025 was reported at ₹0.50 Cr, a slight increase from ₹0.49 Cr in FY 2024. However, this translates to a net profit margin of just 7.60%, which is modest within the pharmaceutical industry. The return on equity (ROE) stood at 5.43%, reflecting a relatively low return for shareholders compared to industry standards, which often exceed 10%. Efficiency ratios reveal a cash conversion cycle of 78.81 days, indicating that while the company is managing its receivables and inventory effectively, the cycle is still on the longer side. Moreover, the interest coverage ratio at 18.70x signifies a strong ability to meet interest obligations, yet the low ROCE of 6.72% suggests that capital employed may not be generating optimal returns, which could concern potential investors looking for higher efficiency in capital utilization.
Balance Sheet Strength and Financial Ratios
The balance sheet of Colinz Laboratories appears fundamentally sound, with total borrowings reported at a mere ₹0.66 Cr against total assets of ₹11.82 Cr, translating to a debt-to-equity ratio of just 0.06. This low leverage indicates a conservative approach to financing, which is generally favorable as it reduces financial risk. Reserves have steadily increased, standing at ₹7.36 Cr, providing a cushion for future investments or downturns. The current ratio of 4.17x and quick ratio of 3.81x suggest strong liquidity, indicating that the company can comfortably meet its short-term liabilities. However, the Price-to-Book ratio (P/BV) of 1.93x indicates that the stock might be priced at a premium compared to its book value, which could be a concern for value-conscious investors. Overall, while the balance sheet reflects strength, the valuation metrics suggest that investors should tread carefully.
Shareholding Pattern and Investor Confidence
Colinz Laboratories has a stable shareholding structure, with promoters holding a commanding 66% stake. This significant insider ownership often reflects confidence in the company’s future prospects and aligns the interests of management with those of shareholders. However, the absence of institutional investors, with both FIIs and DIIs showing negligible participation, raises questions about broader market confidence in the stock. The public holds approximately 34% of the company, and the number of shareholders has seen a gradual increase, reaching 3,272. This uptick suggests growing interest among retail investors, potentially driven by the company’s resilience in a challenging industry. However, the lack of institutional backing could be a red flag, as institutional investors often provide stability and credibility to a stock. Hence, while the promoter’s stake may inspire confidence, the overall investor landscape appears mixed.
Outlook, Risks, and Final Insight
The outlook for Colinz Laboratories presents a blend of opportunities and challenges. The company’s low leverage and strong liquidity position provide a solid foundation for navigating potential market volatility. However, the declining sales trend and modest profitability metrics could hinder growth prospects. Risks include increasing competition in the pharmaceutical sector and potential regulatory challenges that could impact operations. Additionally, the reliance on a limited product line could expose the company to market fluctuations. Investors should consider these factors when evaluating Colinz’s stock. A cautious approach may be warranted, focusing on the company’s ability to innovate and adapt to changing market conditions. Overall, while Colinz Laboratories shows some strengths in terms of its balance sheet and insider ownership, the path ahead requires careful navigation of industry dynamics and an emphasis on improving profitability metrics to truly unlock shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Colinz Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 33.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,117 Cr. | 378 | 479/192 | 85.3 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.9 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,298.69 Cr | 1,151.88 | 51.21 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.84 | 1.92 | 1.68 | 1.72 | 1.90 | 1.79 | 1.71 | 1.63 | 1.75 | 1.86 | 1.47 | 1.45 | 1.57 |
| Expenses | 1.69 | 1.76 | 1.55 | 1.56 | 1.74 | 1.67 | 1.57 | 1.51 | 1.59 | 1.69 | 1.40 | 1.35 | 1.44 |
| Operating Profit | 0.15 | 0.16 | 0.13 | 0.16 | 0.16 | 0.12 | 0.14 | 0.12 | 0.16 | 0.17 | 0.07 | 0.10 | 0.13 |
| OPM % | 8.15% | 8.33% | 7.74% | 9.30% | 8.42% | 6.70% | 8.19% | 7.36% | 9.14% | 9.14% | 4.76% | 6.90% | 8.28% |
| Other Income | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.08 | 0.05 | 0.11 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Profit before tax | 0.15 | 0.17 | 0.13 | 0.16 | 0.16 | 0.16 | 0.15 | 0.19 | 0.19 | 0.21 | 0.11 | 0.13 | 0.16 |
| Tax % | 20.00% | 29.41% | 23.08% | 18.75% | 18.75% | 25.00% | 26.67% | 31.58% | 26.32% | 23.81% | 45.45% | -23.08% | 25.00% |
| Net Profit | 0.11 | 0.12 | 0.10 | 0.13 | 0.12 | 0.12 | 0.11 | 0.14 | 0.14 | 0.16 | 0.05 | 0.15 | 0.12 |
| EPS in Rs | 0.24 | 0.26 | 0.22 | 0.28 | 0.26 | 0.26 | 0.24 | 0.31 | 0.31 | 0.35 | 0.11 | 0.33 | 0.26 |
Last Updated: August 19, 2025, 8:55 pm
Below is a detailed analysis of the quarterly data for Colinz Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1.57 Cr.. The value appears strong and on an upward trend. It has increased from 1.45 Cr. (Mar 2025) to 1.57 Cr., marking an increase of 0.12 Cr..
- For Expenses, as of Jun 2025, the value is 1.44 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.35 Cr. (Mar 2025) to 1.44 Cr., marking an increase of 0.09 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.10 Cr. (Mar 2025) to 0.13 Cr., marking an increase of 0.03 Cr..
- For OPM %, as of Jun 2025, the value is 8.28%. The value appears strong and on an upward trend. It has increased from 6.90% (Mar 2025) to 8.28%, marking an increase of 1.38%.
- For Other Income, as of Jun 2025, the value is 0.08 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.08 Cr..
- For Interest, as of Jun 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.02 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.03 Cr. (Mar 2025) to 0.04 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Mar 2025) to 0.16 Cr., marking an increase of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -23.08% (Mar 2025) to 25.00%, marking an increase of 48.08%.
- For Net Profit, as of Jun 2025, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.12 Cr., marking a decrease of 0.03 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.26. The value appears to be declining and may need further review. It has decreased from 0.33 (Mar 2025) to 0.26, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 6.35 |
| Expenses | 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.88 |
| Operating Profit | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.47 |
| OPM % | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 7.40% |
| Other Income | 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.32 |
| Interest | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.13 |
| Profit before tax | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.61 |
| Tax % | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | |
| Net Profit | 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.48 |
| EPS in Rs | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.01 | 1.07 | 1.09 | 1.05 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 42.86% | -10.00% | 55.56% | 64.29% | -47.83% | 8.33% | 61.54% | 61.90% | 35.29% | 6.52% | 2.04% |
| Change in YoY Net Profit Growth (%) | 0.00% | -52.86% | 65.56% | 8.73% | -112.11% | 56.16% | 53.21% | 0.37% | -26.61% | -28.77% | -4.48% |
Colinz Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 31% |
| 3 Years: | 14% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 40% |
| 3 Years: | 3% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:39 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.36 |
| Borrowings | 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.66 |
| Other Liabilities | 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 1.59 |
| Total Liabilities | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
| Fixed Assets | 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.62 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.21 |
| Other Assets | 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 9.30 |
| Total Assets | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
Below is a detailed analysis of the balance sheet data for Colinz Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.52 Cr..
- For Reserves, as of Sep 2025, the value is 7.36 Cr.. The value appears strong and on an upward trend. It has increased from 6.96 Cr. (Mar 2025) to 7.36 Cr., marking an increase of 0.40 Cr..
- For Borrowings, as of Sep 2025, the value is 0.66 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.64 Cr. (Mar 2025) to 0.66 Cr., marking an increase of 0.02 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.59 Cr.. The value appears to be improving (decreasing). It has decreased from 1.70 Cr. (Mar 2025) to 1.59 Cr., marking a decrease of 0.11 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.82 Cr. (Mar 2025) to 12.13 Cr., marking an increase of 0.31 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1.62 Cr.. The value appears to be declining and may need further review. It has decreased from 1.70 Cr. (Mar 2025) to 1.62 Cr., marking a decrease of 0.08 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.21 Cr.. The value appears strong and on an upward trend. It has increased from 1.04 Cr. (Mar 2025) to 1.21 Cr., marking an increase of 0.17 Cr..
- For Other Assets, as of Sep 2025, the value is 9.30 Cr.. The value appears strong and on an upward trend. It has increased from 9.08 Cr. (Mar 2025) to 9.30 Cr., marking an increase of 0.22 Cr..
- For Total Assets, as of Sep 2025, the value is 12.13 Cr.. The value appears strong and on an upward trend. It has increased from 11.82 Cr. (Mar 2025) to 12.13 Cr., marking an increase of 0.31 Cr..
Notably, the Reserves (7.36 Cr.) exceed the Borrowings (0.66 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.54 | -2.07 | -1.35 | -0.35 | -0.07 | -0.33 | -0.07 | -0.65 | 0.11 | 0.36 | -0.03 | -0.15 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 |
| Inventory Days | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 |
| Days Payable | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 |
| Cash Conversion Cycle | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 |
| Working Capital Days | 89.65 | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 72.66 |
| ROCE % | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Diluted EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Cash EPS (Rs.) | 2.49 | 2.45 | 2.33 | 1.52 | 0.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Revenue From Operations / Share (Rs.) | 25.91 | 27.91 | 28.40 | 19.67 | 17.37 |
| PBDIT / Share (Rs.) | 3.15 | 3.25 | 3.10 | 2.13 | 0.93 |
| PBIT / Share (Rs.) | 2.63 | 2.73 | 2.59 | 1.57 | 0.93 |
| PBT / Share (Rs.) | 2.46 | 2.58 | 2.38 | 1.35 | 0.69 |
| Net Profit / Share (Rs.) | 1.97 | 1.93 | 1.81 | 0.95 | 0.58 |
| PBDIT Margin (%) | 12.14 | 11.63 | 10.91 | 10.85 | 5.38 |
| PBIT Margin (%) | 10.13 | 9.78 | 9.11 | 7.96 | 5.38 |
| PBT Margin (%) | 9.48 | 9.25 | 8.38 | 6.88 | 3.98 |
| Net Profit Margin (%) | 7.60 | 6.92 | 6.39 | 4.86 | 3.37 |
| Return on Networth / Equity (%) | 5.24 | 5.43 | 5.61 | 4.41 | 2.84 |
| Return on Capital Employeed (%) | 6.85 | 7.49 | 7.81 | 6.99 | 4.41 |
| Return On Assets (%) | 4.20 | 4.28 | 4.47 | 3.41 | 2.05 |
| Total Debt / Equity (X) | 0.06 | 0.06 | 0.03 | 0.06 | 0.13 |
| Asset Turnover Ratio (%) | 0.56 | 0.65 | 0.70 | 0.69 | 0.65 |
| Current Ratio (X) | 4.17 | 4.00 | 4.15 | 3.72 | 2.82 |
| Quick Ratio (X) | 3.81 | 3.62 | 3.66 | 3.26 | 2.34 |
| Inventory Turnover Ratio (X) | 0.68 | 0.56 | 0.66 | 0.55 | 0.37 |
| Interest Coverage Ratio (X) | 18.70 | 21.98 | 14.93 | 10.03 | 3.83 |
| Interest Coverage Ratio (Post Tax) (X) | 12.71 | 14.08 | 9.75 | 5.49 | 3.40 |
| Enterprise Value (Cr.) | 13.34 | 3.03 | 3.36 | 3.63 | -0.99 |
| EV / Net Operating Revenue (X) | 2.04 | 0.43 | 0.46 | 0.52 | -0.16 |
| EV / EBITDA (X) | 16.82 | 3.70 | 4.30 | 4.79 | -3.00 |
| MarketCap / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| Price / BV (X) | 1.93 | 1.06 | 1.08 | 1.09 | 0.36 |
| Price / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| EarningsYield | 0.02 | 0.05 | 0.05 | 0.04 | 0.07 |
After reviewing the key financial ratios for Colinz Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.45 (Mar 24) to 2.49, marking an increase of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.91. It has decreased from 27.91 (Mar 24) to 25.91, marking a decrease of 2.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.15. This value is within the healthy range. It has decreased from 3.25 (Mar 24) to 3.15, marking a decrease of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.63. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.63, marking a decrease of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 2.58 (Mar 24) to 2.46, marking a decrease of 0.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.14. This value is within the healthy range. It has increased from 11.63 (Mar 24) to 12.14, marking an increase of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 9.78 (Mar 24) to 10.13, marking an increase of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.25 (Mar 24) to 9.48, marking an increase of 0.23.
- For Net Profit Margin (%), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 7.60, marking an increase of 0.68.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 5.43 (Mar 24) to 5.24, marking a decrease of 0.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.85. This value is below the healthy minimum of 10. It has decreased from 7.49 (Mar 24) to 6.85, marking a decrease of 0.64.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has decreased from 4.28 (Mar 24) to 4.20, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.65 (Mar 24) to 0.56, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 4.17. This value exceeds the healthy maximum of 3. It has increased from 4.00 (Mar 24) to 4.17, marking an increase of 0.17.
- For Quick Ratio (X), as of Mar 25, the value is 3.81. This value exceeds the healthy maximum of 2. It has increased from 3.62 (Mar 24) to 3.81, marking an increase of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 4. It has increased from 0.56 (Mar 24) to 0.68, marking an increase of 0.12.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.70. This value is within the healthy range. It has decreased from 21.98 (Mar 24) to 18.70, marking a decrease of 3.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.71. This value is within the healthy range. It has decreased from 14.08 (Mar 24) to 12.71, marking a decrease of 1.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.34. It has increased from 3.03 (Mar 24) to 13.34, marking an increase of 10.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.04. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 2.04, marking an increase of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 16.82. This value exceeds the healthy maximum of 15. It has increased from 3.70 (Mar 24) to 16.82, marking an increase of 13.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For Price / BV (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.93, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Colinz Laboratories Ltd:
- Net Profit Margin: 7.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.85% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.71
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 43.7 (Industry average Stock P/E: 51.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Industry not found | Address not found | Contact not found |
FAQ
What is the intrinsic value of Colinz Laboratories Ltd?
Colinz Laboratories Ltd's intrinsic value (as of 08 December 2025) is 41.82 which is 4.95% lower the current market price of 44.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 20.1 Cr. market cap, FY2025-2026 high/low of 88.7/36.1, reserves of ₹7.36 Cr, and liabilities of 12.13 Cr.
What is the Market Cap of Colinz Laboratories Ltd?
The Market Cap of Colinz Laboratories Ltd is 20.1 Cr..
What is the current Stock Price of Colinz Laboratories Ltd as on 08 December 2025?
The current stock price of Colinz Laboratories Ltd as on 08 December 2025 is 44.0.
What is the High / Low of Colinz Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Colinz Laboratories Ltd stocks is 88.7/36.1.
What is the Stock P/E of Colinz Laboratories Ltd?
The Stock P/E of Colinz Laboratories Ltd is 43.7.
What is the Book Value of Colinz Laboratories Ltd?
The Book Value of Colinz Laboratories Ltd is 21.6.
What is the Dividend Yield of Colinz Laboratories Ltd?
The Dividend Yield of Colinz Laboratories Ltd is 0.00 %.
What is the ROCE of Colinz Laboratories Ltd?
The ROCE of Colinz Laboratories Ltd is 6.72 %.
What is the ROE of Colinz Laboratories Ltd?
The ROE of Colinz Laboratories Ltd is 5.43 %.
What is the Face Value of Colinz Laboratories Ltd?
The Face Value of Colinz Laboratories Ltd is 10.0.